gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 27 Aug 2015.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, V1a, STAT3
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Supplier
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
Further evidence for sustained systemic inflammation in xenograft recipients (SIXR).
New
Cooper et al., Pittsburgh, United States. In Xenotransplantation, 21 Sep 2015
An IL-6R antagonist suppressed the increase in CRP, but not D-dimer.
Inflammatory Markers Change with Age, but do not Fall Beyond Reported Normal Ranges.
New
Paczek et al., Warsaw, Poland. In Arch Immunol Ther Exp (warsz), 18 Sep 2015
UNASSIGNED: We examined the serum levels of IL-6, IL-8, TNF, IL-6R, TNF-R1, and CRP and the dynamics of changes in these levels according to age.
SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of (99m)Tc-HYNIC-Aca-LSLITRL.
New
Ma et al., Wuhan, China. In Amino Acids, 09 Sep 2015
The SPECT imaging of interleukin-6 receptor and biodistribution studies showed that (99m)Tc-HYNIC-Aca-LSLITRL had higher tumor uptake and significantly lower kidney accumulation compared to (99m)Tc-HYNIC-Aca-TLQASIL. (99m)Tc-HYNIC-Aca-LSLITRL could be a promising agent for SPECT imaging of interleukin-6 receptor of ovarian cancer especially for those anti-IL-6R drugs under clinical trials, such as tocilizumab.
Glycoprotein130 (Gp130) / Interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone.
New
Sims et al., Australia. In Bone, 06 Sep 2015
UNASSIGNED: Interleukin-6 (IL-6) and interleukin-11 (IL-11) receptors (IL-6R and IL-11R, respectively) are both expressed in osteoclasts and transduce signal via the glycoprotein130 (gp130) co-receptor, but the physiological role of this pathway is unclear.
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.
New
Nör et al., Ann Arbor, United States. In Oncotarget, 15 Jul 2015
Here, we investigated whether inhibition of IL-6 receptor (IL-6R) signaling with tocilizumab (humanized anti-human IL-6R antibody) sensitizes MEC to chemotherapy using human mucoepidermoid carcinoma cell lines (UM-HMC) and correspondent xenograft models.
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
Review
New
Rose-John et al., Kiel, Germany. In Curr Opin Immunol, Jun 2015
However, a plethora of studies in the last decade has convincingly shown that only signaling via the soluble IL-6R (trans-signaling) accounts for the deleterious effects of IL-6, whereas classic signaling via the membrane-bound receptor is essential for the regenerative and anti-bacterial effects of IL-6 (classic signaling).
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
New
Impact
Hill et al., Brisbane, Australia. In Lancet Oncol, Dec 2014
Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways.
Role of interleukin-6 in cachexia: therapeutic implications.
Review
New
Carson et al., Columbia, United States. In Curr Opin Support Palliat Care, Dec 2014
IL-6 trans-signaling through the soluble IL-6R has the potential to amplify IL-6 signaling in the cachectic patient.
Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
New
Impact
Mauri et al., Udine, Italy. In Nat Med, Nov 2014
Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals.
Interleukin-6 and its receptors: a highly regulated and dynamic system.
Review
New
Garbers et al., Kiel, Germany. In Cytokine, Nov 2014
IL-6 induces intracellular signaling pathways after binding to its membrane-bound receptor (IL-6R), which is only expressed on hepatocytes and certain subpopulations of leukocytes (classic signaling).
Chimeric antigen receptor T cells for sustained remissions in leukemia.
New
Impact
Grupp et al., Australia. In N Engl J Med, Nov 2014
Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.
Immunotherapy for Graves' ophthalmopathy.
Review
New
Salvi, Milano, Italy. In Curr Opin Endocrinol Diabetes Obes, Oct 2014
A recent open study with tocilizumab, an anti-soluble interleukin-6 receptor, has shown inactivation of Graves' ophthalmopathy.
Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Review
New
Grupp et al., Philadelphia, United States. In Cancer J, Mar 2014
One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab.
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Review
Impact
Weiss et al., Toronto, Canada. In Nat Rev Immunol, 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
Impact
PRCSG et al., Roma, Italy. In N Engl J Med, 2013
METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
GeneRIF
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
GeneRIF
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
GeneRIF
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Impact
GeneRIF
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
GeneRIF
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
share on facebooktweetadd +1mail to friends